Repligen develops novel therapeutics for the treatment of diseases of the central nervous system. It also sells Protein A products, which can be used for diagnostic purposes, including the detection of pancreatic disorders.
The company also conducts its own drug development programs for schizophrenia, bipolar disorder, and neurodegeneration. The $104 million company has $19.5 million in cash and no debt according to the latest Yahoo! financial data. Yearly Revenue has been increasing for the last 3 years, and in fact, the company recorded its first yearly profit in 2006.
Shares of Repligen closed at $3.43, a little more than 20% away from the 52-week high of $4.17.
Repligen has made BHI's BioWatch Alert List.